LSV Asset Management
EGRX

LSV Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

LSV Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-295,388
Closed -$1.65M – 891
2024
Q2 		$1.65M Sell
295,388
-38,770
-12% -$169K ﹤0.01% 625
2024
Q1 		$1.75M Sell
334,158
-57,600
-15% -$316K ﹤0.01% 624
2023
Q4 		$2.05M Sell
391,758
-17,000
-4% -$168K ﹤0.01% 617
2023
Q3 		$6.45M Hold
408,758
– – 0.02% 487
2023
Q2 		$7.95M Buy
408,758
+165,022
+68% +$3.91M 0.02% 461
2023
Q1 		$6.92M Buy
243,736
+92,318
+61% +$2.74M 0.02% 475
2022
Q4 		$4.43M Buy
+151,418
New +$4.81M 0.01% 529
2021
Q1 		– Sell
-3,289
Closed -$153K – 951
2020
Q4 		$153K Sell
3,289
-10,511
-76% -$492K ﹤0.01% 885
2020
Q3 		$586K Sell
13,800
-154,701
-92% -$6.77M ﹤0.01% 786
2020
Q2 		$8.08M Sell
168,501
-151,726
-47% -$7.57M 0.02% 471
2020
Q1 		$14.7M Sell
320,227
-48,950
-13% -$2.46M 0.04% 345
2019
Q4 		$22.2M Sell
369,177
-92,381
-20% -$5.51M 0.03% 369
2019
Q3 		$26.1M Buy
461,558
+57,189
+14% +$3.22M 0.04% 332
2019
Q2 		$22.5M Buy
404,369
+154,365
+62% +$8.05M 0.04% 359
2019
Q1 		$12.6M Buy
250,004
+166,715
+200% +$7.42M 0.02% 438
2018
Q4 		$3.35M Sell
83,289
-6,052
-7% -$312K 0.01% 617
2018
Q3 		$6.19M Sell
89,341
-503,301
-85% -$38.2M 0.01% 577
2018
Q2 		$44.8M Sell
592,642
-266,500
-31% -$16.8M 0.07% 268
2018
Q1 		$45.3M Buy
859,142
+125,320
+17% +$7.29M 0.07% 257
2017
Q4 		$39.2M Buy
733,822
+506,028
+222% +$28.2M 0.06% 278
2017
Q3 		$13.6M Buy
+227,794
New +$13.8M 0.02% 435

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

LSV Asset Management's EGRX Position: Q3 2024 in Review

LSV Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 295,388 shares — an estimated $1.65M sold.

LSV Asset Management first reported a position in EGRX in Q3 2017 and held it in 21 quarters. The position peaked at $45.3M in Q1 2018. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • LSV Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • LSV Asset Management sold 295,388 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $1.65M.
  • LSV Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 21 quarters.
  • LSV Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $45.3M in Q1 2018.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on LSV Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.